earnings
confidence high
sentiment neutral
materiality 0.60
Caribou Q1 2026 rev flat at $2.4M; FDA aligns on pivotal trial for vispa-cel
Caribou Biosciences, Inc.
2026-Q1 EPS reported
-$0.26
revenue$2,397,000
- FDA alignment on ANTLER-3 pivotal phase 3 trial for vispa-cel in 2L LBCL; primary endpoint PFS, crossover allowed.
- Cash and marketable securities $118.6M as of Mar 31, 2026; expected to fund into 2H 2027.
- R&D expenses down to $20.6M from $35.5M; G&A down to $8.1M from $9.7M YoY.
- CB-011 granted RMAT for r/r MM; enrollment ongoing, dose expansion data expected 2026.